# Juan M. Mejía‐Vilet

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/juan-m-mejia-vilet/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,971 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 28 |
| i10-index | 48 |
| Last Known Institution | Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán |
| OpenAlex ID | https://openalex.org/A5004615717 |
| ORCID iD | 0000-0003-4062-9412 |
| Works | 114 |

## Researcher papers

- [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdigo-2021-clinical-practice-guideline-for-the-management-of-glomerular-diseases/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS](https://scholariq.org/papers/kdigo-2024-clinical-practice-guideline-for-the-management-of-lupus-nephritis/)
- [Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-1-conclusions-from-a-kidney/)
- [Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-2-conclusions-from-a-kidney/)
- [Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone](https://scholariq.org/papers/renal-ischemia-reperfusion-injury-is-prevented-by-the-mineralocorticoid-receptor/)
- [Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis](https://scholariq.org/papers/urinary-soluble-cd163-a-novel-noninvasive-biomarker-of-activity-for-lupus/)
- [Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement](https://scholariq.org/papers/clinical-presentation-and-outcome-prediction-of-clinical-serological-and/)
- [The lupus nephritis management renaissance](https://scholariq.org/papers/the-lupus-nephritis-management-renaissance/)
- [Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis](https://scholariq.org/papers/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the/)
- [Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis](https://scholariq.org/papers/voclosporin-a-novel-calcineurin-inhibitor-for-the-management-of-lupus-nephritis/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

## Researcher university

- [Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán](https://scholariq.org/institutions/instituto-nacional-de-ciencias-medicas-y-nutricion-salvador-zubiran/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.